Line graph titled 'Cost-Effectiveness of text@1, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy'. The graph shows cost-effectiveness acceptability curve with 'Optimal probability strategy, %' on the Y-axis and 'Cost-effectiveness threshold (2025 $/QALY gained)' on the X-axis. Lines represent ApoB goal, Non-HDL-C goal, and LDL-C goal.

A computer simulation found #ApoB-guided intensification of lipid-lowering therapy provides the most QALYs and is highly cost-effective compared to #LDL-C or #nonHDL-C targets.

ja.ma/4cxfzKX